Joy-Yan Lam

Dr. Joy-Yan Lam

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CYChun-Kit Yuen
Chun-Kit Yuen
WWWan-Man Wong
Wan-Man Wong
LMLong-Fung Mak
Long-Fung Mak
JLJoy-Yan Lam
Joy-Yan Lam
LCLok-Yi Cheung
Lok-Yi Cheung
KKKin-Hang Kok
Kin-Hang Kok
A pan-sarbecovirus or pan-betacoronavirus vaccine that can prevent current and potential future beta-coronavirus infections is important for fighting possible future pandemics. Here, we report a mucosal vaccine that cross-protects small animal models from sarbecoviruses including SARS-CoV-1, SARS-CoV-2 and its variants. The vaccine comprises a live-but-defective SARS-CoV-2 virus that is envelope deficient and has the orf8 segment replaced by interferon-beta, hence named Interferon Beta Integrated SARS-CoV-2 (IBIS) vaccine. Nasal vaccination with IBIS protected mice from lethal homotypic SARS-CoV-2 infection and hamsters from co-housing-mediated transmission of homotypic virus. Moreover, IBIS provided complete protection against heterotypic sarbecoviruses, including SARS-CoV-2 Delta and Omicron variants, and SARS-CoV-1 in both mice and hamsters. Besides inducing a strong lung CD8 + T cell response, IBIS specifically heightened the activation of mucosal virus-specific CD4 + T cells compared to the interferon-null vaccine. The direct production of interferon by IBIS also suppressed virus co-infection of SARS-CoV-2 in human cells, reducing the risk of genetic recombination when using as live vaccines. Altogether, IBIS is a next-generation pan-sarbecovirus vaccine and warrants further clinical investigations.

29 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
JLJoy-Yan Lam
Joy-Yan Lam
WWWan-Man Wong
Wan-Man Wong
CYChun-Kit Yuen
Chun-Kit Yuen
YNYau-Yee Ng
Yau-Yee Ng
CSChun-Hin San
Chun-Hin San
KKKin-Hang Kok
Kin-Hang Kok
Developing recombinant proteins as nasal vaccines for inducing systemic and mucosal immunity against respiratory viruses is promising. However, additional adjuvants are required to overcome the low immunogenicity of protein antigens. Here, a self-adjuvanted protein-RNA ribonucleoprotein vaccine was developed and found to be an effective nasal vaccine in mice and the SARS-CoV-2 infection model. The vaccine consisted of spike RBD (as an antigen), nucleoprotein (as an adaptor), and ssRNA (as an adjuvant and RNA scaffold). This combination robustly induced mucosal IgA, neutralizing antibodies and activated multifunctional T-cells, while also providing sterilizing immunity against live virus challenge. In addition, high-resolution scRNA-seq analysis highlighted airway-resident immune cells profile during prime-boost immunization. The vaccine also possesses modularity (antigen/adaptor/RNA scaffold) and can be made to target other viruses. This protein-RNA ribonucleoprotein vaccine is a novel and promising approach for developing safe and potent nasal vaccines to combat respiratory virus infections.

Verified
Journal Article
Open access
PDF file
JLJoy-Yan Lam
Joy-Yan Lam
KKKin-Hang Kok
Kin-Hang Kok
The SARS-CoV-2 ORF8 protein is a unique accessory viral protein among human coronaviruses, characterized by recurrent deletions and mutations with functional consequences. In this short report, we demonstrate that several dominant SARS-CoV-2 strains, despite encoding ORF8, fail to secrete the protein, revealing a recurring pattern of ORF8 functional impairment that cannot be detected by sequence analysis alone. In agreement with other studies, several high-frequency mutations were identified using the Nextstrain/augur pipeline, including G8Stop, Q27Stop, D119-/F120- double deletions, and nucleotide substitution C27889U, which occurred in XBB.1.5, Alpha, Delta, and BA.5.2 variants, respectively. Notably, the D119-/F120- deletions and C27889U substitution do not introduce premature stop codons, yet ORF8 secretion was lost in Delta and BA.5.2 virus-infected cultures. This indicates that the extracellular ORF8 function is impaired in these variants, resulting in ORF8 deficiency. Our findings highlight that the impairment of ORF8 secretion arises not only from premature stop codons but also from other mutations. Therefore, the functional validation of ORF8 secretion and activity is essential following sequence analysis to accurately assess ORF8’s role in SARS-CoV-2 infection.

21 March 2026 in EBioMedicine
Verified
Journal Article
Open access
JLJoy-Yan Lam
Joy-Yan Lam
CYChun-Kit Yuen
Chun-Kit Yuen
SCShuk-Kwan Cheung
Shuk-Kwan Cheung
PCPak-Him Cheung
Pak-Him Cheung
KYKwok-Yung Yuen
Kwok-Yung Yuen
KKKin-Hang Kok
Kin-Hang Kok
Recent cases of H5N1 avian influenza spilling over into human populations have raised concerns once again about the unpredictable emergence of zoonotic viral diseases. This phenomenon highlights the persistent threat posed by viruses that jump from animals to humans, underscoring the need for preparedness for antigens that humans have not encountered. Nasal vaccines, which can effectively block transmission at the site of viral entry, represent a promising strategy and should be prioritised for stockpiling to halt zoonotic spillover. Here, we immunised a preclinical animal model intranasally with the RNA-Scaffold-Protein Vaccine (RSPVac) and evaluated mucosal immunity and protection against avian-origin and pandemic human influenza viruses. Nasal immunisation of strain-specific H5N1 and H1N1 RSPVac induced strong antibody responses in serum and mucosa, accompanied by mucosal antigen-specific T cells. We examined immune cells during early vaccination and found that RSPVac induced a strong but transient cytokine expression. Neutrophils comprising both regulatory and effector subsets were observed, indicating a controlled activation. Vaccinated animals were completely protected against vaccine-matched avian virus challenges without pathological signs. Protection was also observed against vaccine-unmatched H1N1 and H7N9 challenges, with a display of trained immune cell profiles. Finally, mutant RSPVac demonstrated an impaired vaccination outcome, suggesting a complex activation mechanism. These findings demonstrate that RSPVac elicits potent mucosal immunity and safeguards against vaccine-unmatched infections, underscoring its potential as a non-infectious mucosal vaccine to prevent zoonotic virus transmission. This study is supported by the Health@InnoHK initiative of the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government.